Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
Jonsson Comprehensive Cancer Center
Modality
Small molecule
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05319873CT.gov Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Invasive Breast Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ribociclib (this asset) | Jonsson Comprehensive Cancer Center | P1/2 | CC · 47 |
| Tamoxifen | University of California, San Francisco | P4 | BBB |
| Letrozole | Emory University | P4 | BBB |
| Exemestane | University of California, San Francisco | P4 | BBB |
| Anastrozole | Jonsson Comprehensive Cancer Center | P4 | BBB |
| Fulvestrant | Massachusetts General Hospital | P2 | BB |
| Carboplatin | Baylor Breast Care Center | P3 | BB |
| Trastuzumab | Massachusetts General Hospital | P3 | BB |
| Pertuzumab | Baylor Breast Care Center | P3 | BB |
+42 more in the Invasive Breast Carcinoma cohort
Other indications for Ribociclib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hormone Receptor-Positive Breast Cancer | — | P4 | BBB · 73 |
| Breast Cancer | — | P4 | BB · 70 |
| Estrogen-Receptor Positive Breast Cancer | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ribociclib in Invasive Breast Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ribociclib-invasive-breast-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →